Objective:
To announce the FDA approval of the RayOne EMV Toric intraocular lens for patients with astigmatism.
Key Findings:
- RayOne EMV Toric demonstrated an absolute mean rotation of just 0.9° at 1 and 2 days post-operation.
- At 6 months, the absolute mean lens alignment was 3.5°, with 99% of eyes rotating ≤5°.
- The lens design utilizes a patented nondiffractive optic, providing high-quality vision and low dysphotopsia.
Interpretation:
The results indicate that RayOne EMV Toric offers excellent rotational stability and visual performance, surpassing FDA requirements.
Limitations:
Conclusion:
The RayOne EMV Toric lens is now available for US surgeons, enhancing options for astigmatism correction with high-quality visual outcomes.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.